Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $77.92, marking a +1.1% move from the previous day.

5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Tirthankar Chakraborty headshot

Wall Street Just Got Hammered: Grab 5 Ultra-Safe Stocks Now

by Tirthankar Chakraborty

With Wall Street seeing its worst one-day selloff on Jan 27 since October 2020 and with the bearish trend likely to continue, it's safe to bet on stocks like Allete (ALE), B&G Foods (BGS) and Merck (MRK).

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

by Zacks Equity Research

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer

by Zacks Equity Research

The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat

by Zacks Equity Research

J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.

Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer

by Zacks Equity Research

The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.

Bayer (BAYRY) Gets a Boost With Product Approvals and Deals

by Zacks Equity Research

Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

by Zacks Equity Research

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC

by Zacks Equity Research

Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.

Merck (MRK) Stock Moves -0.25%: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $80.98, moving -0.25% from the previous trading session.

Urmimala Biswas headshot

5 Finest PEG Stocks for GARP Investors

by Urmimala Biswas

Here are five picks out of 45 top-ranked stocks with discounted PEG.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal

by Kinjel Shah

Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.

Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review

by Zacks Equity Research

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod

by Zacks Equity Research

Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction

AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.

Cocrystal Pharma (COCP) Completes Research Obligations With Merck

by Zacks Equity Research

Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.

Why Merck (MRK) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

by Zacks Equity Research

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.

AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing

by Zacks Equity Research

AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.

Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

by Zacks Equity Research

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

by Kinjel Shah

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

Merck (MRK) Stock Moves -0.21%: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $82.17 in the latest trading session, marking a -0.21% move from the prior day.